Haemophilus b Conjugate - Meningococcal Protein Conjugate Vaccine (Pedvax HIB, Menhibrix)
Jump to navigation
Jump to search
Indications
- routine vaccination against invasive disease caused by Haemophilus influenzae type b in infants & children 2-71 months of age
- high risk* infants (MenHibrix)[3][4]
- complement component deficiency
- functional or anatomical asplenia[4]
- Menhibrix is FDA-approved to prevent infection by Neisseria meningitidis serogroups C & Y & Haemophilus influenzae type b[2]
Dosage
- IM only
- 1st dose 2-14 months
- booster at 15 months or older (regardless of number of doses given < 15 months)
- Menhibrix is a 4 dose series given at 2, 4, 6 & 12-15 months of age
Mechanism of action
- Pedvax HIB is a highly purified capsular polysaccharide (polyribosylribitol phosphate or PRP) of Haemophilus influenzae type b (Haemophilus b, Ross strain) that is covalently bound to an outer membrane protein complex (OMPC) of the B11 strain of Neisseria meningitidis serogroup B
More general terms
Component of
- haemophilus b conjugate meningococcal protein conjugate vaccine/hepatitis b vaccine
- hepatitis b vaccine/haemophilus b conjugate vaccine meningococcal protein conjugate
References
- ↑ RxList http://www.rxlist.com/pedvaxhib-drug.htm
- ↑ 2.0 2.1 FDA News, June 14, 2012 FDA approves new combination vaccine that protects children against two bacterial diseases http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm308350.htm
- ↑ 3.0 3.1 Reuters, Oct 24, 2012 CDC panel OKs Glaxo's meningitis vaccine for at-risk infants http://news.yahoo.com/cdc-panel-oks-glaxos-meningitis-vaccine-risk-infants-194542818--finance.html
- ↑ 4.0 4.1 4.2 Centers for Disease Control and Prevention Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) Recommendations and Rationale. MMWR. January 25, 2013 / 62(03);52-54 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a3.htm